Quantcast
Last updated on April 23, 2014 at 12:08 EDT

Latest MedImmune Stories

2012-03-15 20:20:00

BLUE BELL, Pa., March 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2011. Total revenue was $1.6 million and $9.8 million for the quarter and year ended December 31, 2011, compared to $2.4 million and $6.1 million for the same periods in 2010. Total operating expenses for the quarter and year ended December 31, 2011, were $7.4 million and $31.4 million as compared to $7.6 million...

2012-02-29 18:20:00

GAITHERSBURG, Md., Feb. 29, 2012 /PRNewswire/ -- MedImmune today announced that the U.S. Food and Drug Administration (FDA) has approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of influenza. The company submitted the sBLA early in the second quarter of last year. FluMist Quadrivalent is the first quadrivalent influenza vaccine approved by the FDA. All other currently available licensed seasonal influenza vaccines are trivalent, containing three strains...

2012-02-22 07:00:00

ROCKVILLE, Md., Feb. 22, 2012 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a new regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in the Central Maryland region, announced today the appointment of its Board of Directors, including Scott Carmer, MedImmune Executive Vice President of Commercial Operations, as Chairman. "The State of Maryland is known as one of the most...

2012-02-16 05:47:00

NES ZIONA, Israel, February 16, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. [http://www.biondvax.com ] (TASE: BNDX) today announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly. The vaccine was found to be safe and well tolerated, and induced robust cellular and humoral immune responses in elderly patients (65+), successfully...

2012-02-02 04:40:00

LONDON, February 2, 2012 /PRNewswire/ -- AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price intervention had reduced its revenues by about $1bn as it announced further restructuring alongside its full-year results. In an interview on http://www.cantos.com, David Brennan, CEO, discusses AstraZeneca's portfolio performance including Brilinta and Crestor, and the prospects for the pipeline in light of recent disappointments. He also...

Generation X Responded Well To Swine Flu
2012-01-25 11:37:44

Generation X Report details 36-39 year olds' first encounter with a major epidemic About one in five young adults in their late 30's received a flu shot during the 2009-2010 swine flu epidemic, a University of Michigan (U-M) study released Jan 24 says. But about 65 percent were at least moderately concerned about the flu, and nearly 60 percent said they were following the issue very or moderately closely. Using survey data collected from approximately 3,000 young adults during the...

2012-01-10 13:14:00

ROCKVILLE, Md., Jan. 10, 2012 /PRNewswire/ -- Biologics drug development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that its customer Sumagen, Co., Ltd., (Seoul, S. Korea and London, ON) will begin clinical trials of their revolutionary HIV vaccine design. The Food and Drug Administration approved Phase I clinical trial will begin in January. The design and testing of the vaccine was spearheaded by Dr. Chil-Yong Kang, a professor at...

2012-01-05 15:44:34

Don't let the new year trick you into thinking that flu season is over. According to an expert at Baylor College of Medicine, flu season is just starting and those who have not yet been vaccinated should still do so. "There is still time to get vaccinated before flu season peaks in February," said Dr. Paul Glezen, professor of molecular virology and microbiology at BCM. Nasal spray Glezen recommends that healthy individuals between the ages of 2 and 49 get the influenza vaccine in...

2012-01-05 07:30:00

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A...

2011-12-15 06:30:00

BOSTON, Dec. 15, 2011 /PRNewswire/ -- Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk. As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to...